BACKGROUND: Severe forms of @entity1569 including @entity1569 , which require a more aggressive therapeutic approach such as phototherapy or systemic therapies, are rarely seen. Systemic @entity137 and long-term safety of these agents are serious concerns in @entity1 . OBJECTIVE: We report our experience on the efficacy and safety of @entity205 treatment in 22 @entity1 of childhood @entity1569 . METHODS: We retrospectively analyzed the records of all @entity1 less than 18 years of age treated with systemic @entity205 therapy at our clinic between January 2000 and March 2009. Demographic features as well as other relevant data including previous therapies, the dosage and duration of @entity205 therapy, response to treatment and side effects were retrieved from the @entity1 ' records. RESULTS: A total of 22 @entity1 were treated with systemic @entity205 therapy. Seventeen @entity1 were found to be excellent responders. The mean therapeutic dosage of @entity205 was 3.47        0.62   mg/kg/day. The mean duration of @entity205 therapy was 5.68        3.29 months. The median time to total clearance of the lesions was 4.0 weeks. CONCLUSION: We conclude that @entity205 therapy is equally effective and safe in pediatric @entity1569 @entity1 as in adults.

Clinical experience with systemic @entity205 treatment in severe childhood XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine A'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis', 'erythrodermic or pustular psoriasis']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
